HighTide Therapeutics Overview
- Year Founded
-
2011
- Status
-
Public
- Employees
-
55
- Stock Symbol
-
02511
- Share Price
-
$0.38
- (As of Thursday Closing)
HighTide Therapeutics General Information
Description
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
Contact Information
Website
www.hightidetx.comCorporate Office
- Floors 9-10, Building D, Shenzhen-Hong Kong Science and Technology Innovation Cooperation
- Fubao Subdistrict, Futian District
- Shenzhen, Guangdong
- China
Corporate Office
- Floors 9-10, Building D, Shenzhen-Hong Kong Science and Technology Innovation Cooperation
- Fubao Subdistrict, Futian District
- Shenzhen, Guangdong
- China
HighTide Therapeutics Stock Performance
As of 12-Nov-2026, HighTide Therapeutics’s stock price is $0.38. Its current market cap is $228M with 607M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.38 | $0.38 | $0.23 - $0.60 | $228M | 607M | 436K | -$0.08 |
HighTide Therapeutics Financials Summary
As of 30-Jun-2026, HighTide Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 128,743 | 172,262 | 7,443 | 957,870 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (40,388) | (32,298) | (54,608) | (135,847) |
| Net Income | (36,854) | (32,275) | (53,207) | (132,766) |
| Total Assets | 55,702 | 78,800 | 76,702 | 112,157 |
| Total Debt | 22,777 | 18,132 | 10,672 | 2,318 |
HighTide Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
HighTide Therapeutics Comparisons
Industry
Financing
Details
HighTide Therapeutics Competitors (2)
One of HighTide Therapeutics’s 2 competitors is Adlai Nortye, a Formerly VC-backed company based in North Brunswick Township, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adlai Nortye | Formerly VC-backed | North Brunswick Township, NJ | ||||
| Luye Pharma Group | Formerly PE-Backed | Shanghai, China |
HighTide Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
HighTide Therapeutics Patents
HighTide Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026233278-A1 | Compositions and methods for treating polycystic ovary syndrome | Pending | 06-May-2025 | ||
| WO-2026183678-A1 | Novel conjugates and compositions of mitochondrial uncouplers and n-beta-hydroxybutyric phenylalanine derivatives, and methods of use thereof | Pending | 03-Mar-2025 | ||
| WO-2026149336-A1 | Compositions and methods for treating diabetes-related complications | Pending | 07-Jan-2025 | ||
| WO-2026149323-A1 | Compositions and methods of using mitochondrial uncouplers and glp-1 receptor agonists | Pending | 07-Jan-2025 | ||
| WO-2026145494-A1 | Compositions and methods for treating obesity | Pending | 31-Dec-2024 | A61K38/26 |
HighTide Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
HighTide Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
HighTide Therapeutics FAQs
-
When was HighTide Therapeutics founded?
HighTide Therapeutics was founded in 2011.
-
Where is HighTide Therapeutics headquartered?
HighTide Therapeutics is headquartered in Shenzhen, China.
-
What is the size of HighTide Therapeutics?
HighTide Therapeutics has 55 total employees.
-
What industry is HighTide Therapeutics in?
HighTide Therapeutics’s primary industry is Drug Discovery.
-
Is HighTide Therapeutics a private or public company?
HighTide Therapeutics is a Public company.
-
What is HighTide Therapeutics’s stock symbol?
The ticker symbol for HighTide Therapeutics is 02511.
-
What is the current stock price of HighTide Therapeutics?
As of 12-Nov-2026 the stock price of HighTide Therapeutics is $0.38.
-
What is the current market cap of HighTide Therapeutics?
The current market capitalization of HighTide Therapeutics is $228M.
-
Who are HighTide Therapeutics’s competitors?
Adlai Nortye and Luye Pharma Group are competitors of HighTide Therapeutics.
-
What is HighTide Therapeutics’s annual earnings per share (EPS)?
HighTide Therapeutics’s EPS for 12 months was -$0.08.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
